ThromboGenics

FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

posted 5 days ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.thrombogenics.com
Email:
Phone: +32 16 75 13 10
FlandersBio Member
More address details

Business Focus

ThromboGenics (Euronext Brussels: THR) is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company is also developing two novel antibody therapeutics; these are TB-402 (anti-Factor VIII), a long-acting anticoagulant in collaboration with BioInvent International and TB-403 (anti-PIGF) for cancer in partnering with Roche.

Company Profile

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company’s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re-submitted in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon’s net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.

ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer which has been partnered with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.

Science & Technology or Services

The lead product ocriplasmin has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re-submitted in the U.S. for Priority Review. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

Staphylokinase completed a successful Phase III trial with THR-100, a thrombolytic agent for myocardial infarction. THR-100 is a novel variant of recombinant Staphylokinase and is being developed for emerging markets.

TB-402 (anti-Factor VIII): ThromboGenics and co-development partner BioInvent International initiated in April 2011 a Phase IIb trial with TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip replacement surgery.

TB-403 (anti-PlGF) antibody is undergoing a Phase Ib/II multi-center trial to examine the safety and clinical effect of TB-403 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma (brain cancer). ThromboGenics has a major licensing agreeement with Roche, a leading pharmaceutical company.

Product description

ocriplasmin, staphylokinase, TB-402 (anti-factor VIII), TB-403 (anti-PlGF), THR-100 (Staphylokinase)

Alliances

Roche (Switzerland)
ThromboGenics and BioInvent entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.
Rhein Minapharm (Egypt/Middle East)
ThromboGenics and Rhein Minapharm entered into a license agreement for manufacturing, clinical development and commercialization of THR-174, the next-generation derivative of Staphylokinase, in the Middle East, Africa and other countries comprising the MENA region. THR-174 is a recombinantly derived thrombolytic agent developed for treatment of acute myocardial infarction (heart attack).
Bharat Biotech International Limited (India)
ThromboGenics and Bharat Biotech International Limited entered into a license agreement for manufacturing, clinical development and commercialization of THR-100*, a novel variant of Recombinant Staphylokinase, in developing countries and certain industrialized countries. THR-100 is a thrombolytic agent developed for treatment of acute myocardial infarction (heart attack) and other vascular diseases based on its ability to dissolve blood clots.
* formerly known as Sak42D
BioInvent International AB (Sweden)
ThromboGenics and BioInvent International AB entered into a collaborative research and licensing agreement in September 2004 to co-develop antibody-based drugs for vascular indications. Currently, the partners are jointly developing two candidates:
TB-402 (Anti-Factor VIII) as an anticoagulant therapy for numerous indications, including prevention and treatment of deep vein thrombosis and treatment of atrial fibrillation; and
TB-403 (Anti-PlGF) as an anti-angiogenic agent for potential treatment of various diseases, including cancer, age-related macular degeneration, retinopathies and inflammation.
Millipore Corporation (USA)
ThromboGenics and Millipore Corporation entered into a license agreement under which ThromboGenics has licensed its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(TM)*. The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its successful efforts to identify several of its drug discovery candidates currently in clinical trials.
* RESGRO and Chemicon are Milipore owned trademarks. RESGRO is also known as TX-WES Stem Cell Medium
Roche Diagnostics (Switzerland) and Biosite Inc. (USA)
ThromboGenics, along with its partner Geymonat, has entered into two co-exclusive licensing agreements, with Roche Diagnostics and Biosite Inc., for use of PlGF (Placental Growth Factor) in diagnostic applications. ThromboGenics and Geymonat have out-licensed the use of PlGF as a diagnostic marker for the prediction of major cardiac events, such as heart attack, and pre-eclampsia, a disease of pregnancy.
Alcon (Switzerland)
ThromboGenics signed an important strategic deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside the U.S. ThromboGenics will receive up to €375 million in upfront and milestone payments plus royalties commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval.

Academic

ThromboGenics has a wide range of agreements with numerous academic institutes that have significant research expertise in the vascular area, and from which the Company has in-licensed a number of the therapeutic programmes that it currently has under development. These academic institutes include:

Flanders Institute for Biotechnology (VIB)
The Company has an ongoing collaboration with the Center for Transgene Technology and Gene Therapy, a department of the VIB, on the pre-clinical characterisation of two of its programmes that were in-licensed from this institute, Anti-PlGF and PlGF.
Scientific Advisory Boards
In addition to the above collaborations, ThromboGenics has Advisory Boards for several of its advanced programmes (namely, the Microplasmin-Vitreoretinal Advisory Board, the Microplasmin-Stroke Advisory Board, the Anti-Factor VIII Advisory Board, and the Anti-PlGF Advisory Board).